Navigation Links
Neptune Technologies & Bioressources Inc. reports first quarter results
Date:10/10/2008

LAVAL, QC, Oct. 10 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) today announced financial results for the fiscal 2009 first quarter ended August 31, 2008.

Total revenue for the three-month period ended August 31, 2008 was $2,366,000 compared to $2,085,000 for the first quarter ended August 31, 2007, representing an increase of 13.5%.

The Company substantially decreased its net loss by 43% to $599,000, or $0.016 per share, for the three-month period ended August 31, 2008, compared to a net loss of $1,051,000, or $0.029 per share, for the three-month period ended August 31, 2007. Excluding non-monetary items, stock option based compensation and amortization, Neptune would have generated a profit of $344,000 for the three-month period ended August 31, 2008.

Neptune continues to generate positive cash flow during the three months ended August 31, 2008 and the Company's cash, cash equivalents and short-term deposits amounted to $2,151,000 on August 31, 2008. In addition, the Company announced recently that it successfully completed a $2,750,000 debenture financing to be used to support the achievement of several value-creating development and commercialization milestones of Acasti Pharma, its pharmaceutical subsidiary.

About Neptune

Neptune researches and develops proprietary bioactive ingredients and products for nutraceutical and pharmaceutical applications and is carrying out clinical research to show the therapeutic benefits in various medical indications. The Company patents and protects its innovations and continuously expands its intellectual property portfolio. Neptune has already obtained many regulatory approvals allowing commercialization of its products in various geographic markets and has filed for and is expecting additional approvals. Neptune continues to strongly support its strategic development plan to form partnership with worldwide leaders in the nut
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
6. Neptune Technologies receives GRAS notification in the United States
7. Neptune Technologies expands into medicinal markets in Asia Pacific
8. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
9. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015 LifeCell Dx and its founder, ... get an Advanced Semen Analysis before they do anything ... are all risk factors for struggling couples.Too often, the ... source of the infertility. Infertility is fairly equally divided ... the simplest, least complicated and inexpensive analysis that provides ...
(Date:3/5/2015)... March 05, 2015 North Carolina-based ... Noel, M.D., Professor of Medicine, Mayo Clinic College ... Board of Directors. , Entegrion’s Executive ... fortunate to have Dr. Noel, a distinguished physician ... organization, join Entegrion’s Board. His expertise in hematology ...
(Date:3/5/2015)...  In response to the incorrect assertions by LD, ... on February 12, 2015. Impeto Medical SAS and ... and their SUDOSCAN® devices have been proven to provide ... to have the courts decide this dispute rather than ... articles written by Key Opinion Leaders, published by significant ...
(Date:3/4/2015)... March 4, 2015 PDL BioPharma, Inc. (PDL) (NASDAQ: ... for the: , 3.75% Convertible Senior Notes due ... common stock per $1,000 principal amount or approximately $5.72 per ... for the note is adjusted in connection with the regular ... to all stockholders who own shares of PDL on March 5, ...
Breaking Biology Technology:LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
... YORK, April 5, 2011 Sangamo BioSciences, ... Inc. have announced a collaboration to develop a novel ... zinc finger DNA-binding protein (ZFP) technology. The ZFP therapeutic ... an inherited neurodegenerative disease for which there are currently ...
... 2011 The European Commission (EC) has approved, under the ... DuPont Denmark Holding ApS to acquire all of the outstanding ... cash per share. DuPont Denmark Holding ApS is a wholly ... "We are pleased to have achieved one of the ...
... CHAMPAIGN, Ill. With the first observation of thermoelectric ... that graphene transistors have a nanoscale cooling effect that ... engineering professor William King and electrical and computer engineering ... in the April 3 advance online edition of the ...
Cached Biology Technology:Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntington's Disease 2Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntington's Disease 3Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntington's Disease 4European Commission Approves DuPont Tender Offer to Acquire Danisco 2European Commission Approves DuPont Tender Offer to Acquire Danisco 3Self-cooling observed in graphene electronics 2
(Date:2/9/2015)... -- Lintec of America recently announced an exclusive license to ... including sheets, yarns and ribbons, developed at the University ... vast industrial resources of the global Lintec Group, headquartered ... America is forming the Nano-Science and Technology Center (NSTC) ... scaling up the manufacturing and commercialization of nano engineered ...
(Date:2/5/2015)... DIEGO , Jan. 26, 2015   Epic Sciences ... of cancer, today announced that Murali Prahalad , Ph.D., ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which ... Mountain View, Calif. on January 26-28, 2015. ... "CTCs Come of Age as Biomarkers." Last year, Epic Sciences ...
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... levels in the brains of rats to help ... the sensory pathways to make it easier to ... has found. , Their report in the Journal ... people with attention deficit and hyperactivity disorders to ...
... 2003 has resulted in a "remarkable rate of reestablishment" ... an article in the June issue of BioScience. ... A. Hussain of the University of Basrah, writing about ... large marshes in southern Iraq, note that water inflow ...
... implications for understanding kidney disorders, genetics researchers at ... second gene that gives rise to Alagille syndrome, ... The Children's Hospital team previously discovered the first ... found that mutations in the NOTCH2 gene were ...
Cached Biology News:Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 2Ritalin packs punch by elevating norepinephrine, suppressing nerve signal transmissions 3Iraq's marshes show progress toward recovery 2Gene discovery may shed light on kidney disease 2
...
Formulation: Phosphate-buffered saline, pH 7.2, containing 0.09% sodium azide....
Mouse monoclonal [0.T.81] to Lac1 ( Abpromise for all tested applications). Antigen: Recombinant TrpE fusion protein containing full length E. coli Lac1....
Polyclonal Antibody to HADHB...
Biology Products: